Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Foresees Return To Emerging Markets Growth

Executive Summary

The second quarter saw continued declines in GSK's China and wider emerging markets business, but CEO Andrew Witty expects a return to growth in these sectors over the remainder of the year.

You may also be interested in...



Strong 2Q And Fresh UK Investment Signal Few Brexit Blues at GSK

GlaxoSmithKline reported a strong second quarter and along with its core EPS guidance upgrade, this adds momentum to its post-Brexit vote boost.

China Approves First HPV Vaccine But Can GSK Secure Its Lead?

After a decade-long wait, China has finally approved its first HPV vaccine, GSK's Cervarix, handing a lead to the UK-based firm over its US competitor Merck in the world’s second largest pharma market. But with Chinese companies also vying for a slice of the pie, the battle is just beginning, and pricing will be a key element.

Deep China Price Cuts Reveal Complex Considerations

Offering deep price discounts in exchange for inclusion in reimbursement lists is never easy, given companies' need to balance expected benefits in volume gains with their international pricing systems and commercial pressures. But in China the underlying considerations are even more complex, as shown by the latest round of national price reductions for selected drugs.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC097016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel